Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Billing and Coding: MolDX: Proteomics Testing (A59641) - R2 - Effective January 31, 2024 Mar 14, 2024
MolDX: NRAS Genetic Testing (L36335) - R7 - Effective July 27, 2023 Mar 14, 2024
Multi-Jurisdictional CAC Meeting Announcement - MolDX: Biomarker Risk Stratification Testing in DCIS - April 22, 2024, 2 p.m. to 4 p.m. ET Mar 11, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R16 - Effective April 17, 2022 Mar 07, 2024
MolDX: Defining panel services in MolDX (A59685) - Effective February 29, 2024 Feb 29, 2024
Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection (A58168) - R6 - Effective February 29, 2024 Feb 29, 2024
MolDX: Prometheus® IBD sgi Diagnostic® Policy (L37299) - R7 - Effective February 29, 2024 Feb 29, 2024
Billing and Coding: MolDX: Proteomics Testing (A59641) - R1 - Effective January 31, 2024 Feb 22, 2024
Local Coverage Determination (LCD) Finalized - Effective April 1, 2024 Feb 15, 2024
Billing and Coding: FDA Approved CLL Companion Diagnostic Test (A56009) Retirement - Effective March 30, 2023 Feb 08, 2024
Billing and Coding: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (A57421) - R10 - Effective January 1, 2024 Feb 01, 2024
Billing and Coding: MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors (A56103) - R4 - Effective January 1, 2024 Feb 01, 2024
Billing and Coding: Minimal Residual Disease Testing for Hematologic Cancers (A58996) - R5 - Effective January 1, 2024 Feb 01, 2024
Billing and Coding: MolDX: DecisionDX-Melanoma (A57417) Retirement - Effective August 8, 2022 Jan 25, 2024
Sacroiliac Joint Injections and Procedures (A59244) - R4 - Effective January 25, 2024 Jan 25, 2024
Billing and Coding: MolDX: Pharmacogenomics Testing (A57384) - R13 - Effective January 25, 2024 Jan 25, 2024
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58973) - R4 - Effective January 1, 2024 Jan 25, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57526) - R17 - Effective January 1, 2024 Jan 25, 2024
Proposed Local Coverage Determinations - Published for Review and Comments Jan 18, 2024
Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57901) - R6 - Effective January 1, 2024 Jan 18, 2024